Q1 2022 Earnings Estimate for Revance Therapeutics, Inc. Issued By William Blair (NASDAQ:RVNC)

Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) – Analysts at William Blair cut their Q1 2022 EPS estimates for Revance Therapeutics in a note issued to investors on Tuesday, March 1st. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will post earnings per share of ($0.93) for the quarter, down from their […]

Related Keywords

Thomson Reuter ,William Blair ,Angusc Russell ,Allspring Global Investments Holdings ,Securities Exchange Commission ,Zacks Investment Research ,Centaurus Financial Inc ,Financial Corp ,Nasdaq ,Revance Therapeutics Inc ,Proshare Advisors ,Revance Therapeutics ,Get Rating ,Investment Research ,Share Advisors ,Forest Capital Management ,Director Angus ,Exchange Commission ,Nasdaq Rvnc ,Rvnc ,Medical ,Earnings Estimates ,